BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25468267)

  • 1. KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.
    Chin YW; Han SY
    Expert Opin Ther Pat; 2015 Feb; 25(2):135-44. PubMed ID: 25468267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in histone demethylase KDM4 as cancer therapeutic targets.
    Lee DH; Kim GW; Jeon YH; Yoo J; Lee SW; Kwon SH
    FASEB J; 2020 Mar; 34(3):3461-3484. PubMed ID: 31961018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells.
    Berry WL; Janknecht R
    Cancer Res; 2013 May; 73(10):2936-42. PubMed ID: 23644528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oncogenic potential of Jumonji D2 (JMJD2/KDM4) histone demethylase overexpression.
    Young LC; Hendzel MJ
    Biochem Cell Biol; 2013 Dec; 91(6):369-77. PubMed ID: 24219278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unravelling KDM4 histone demethylase inhibitors for cancer therapy.
    Baby S; Gurukkala Valapil D; Shankaraiah N
    Drug Discov Today; 2021 Aug; 26(8):1841-1856. PubMed ID: 34051367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the histone demethylase KDM4A in cancer.
    Guerra-Calderas L; González-Barrios R; Herrera LA; Cantú de León D; Soto-Reyes E
    Cancer Genet; 2015 May; 208(5):215-24. PubMed ID: 25633974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitor scaffold for the histone lysine demethylase KDM4C (JMJD2C).
    Leurs U; Clausen RP; Kristensen JL; Lohse B
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5811-3. PubMed ID: 22917519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compounds and methods for inhibiting histone demethylases: a patent evaluation of US20160102096A1.
    Thaler F; Mercurio C
    Expert Opin Ther Pat; 2016 Dec; 26(12):1367-1370. PubMed ID: 27730846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KDM4 Demethylases: Structure, Function, and Inhibitors.
    Jiang Y; Liu L; Yang ZQ
    Adv Exp Med Biol; 2023; 1433():87-111. PubMed ID: 37751137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase.
    Chandhasin C; Dang V; Perabo F; Del Rosario J; Chen YK; Filvaroff E; Stafford JA; Clarke M
    Anticancer Drugs; 2023 Nov; 34(10):1122-1131. PubMed ID: 37067993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a Novel Benzimidazole Pyrazolone Scaffold That Inhibits KDM4 Lysine Demethylases and Reduces Proliferation of Prostate Cancer Cells.
    Carter DM; Specker E; Przygodda J; Neuenschwander M; von Kries JP; Heinemann U; Nazaré M; Gohlke U
    SLAS Discov; 2017 Aug; 22(7):801-812. PubMed ID: 28346812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer.
    Ye Q; Holowatyj A; Wu J; Liu H; Zhang L; Suzuki T; Yang ZQ
    Am J Cancer Res; 2015; 5(4):1519-30. PubMed ID: 26101715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.
    Korczynska M; Le DD; Younger N; Gregori-Puigjané E; Tumber A; Krojer T; Velupillai S; Gileadi C; Nowak RP; Iwasa E; Pollock SB; Ortiz Torres I; Oppermann U; Shoichet BK; Fujimori DG
    J Med Chem; 2016 Feb; 59(4):1580-98. PubMed ID: 26699912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling KDM4 histone demethylase expression and its association with adverse cytogenetic findings in chronic lymphocytic leukemia.
    Filiú-Braga LDC; Serejo TRT; Lucena-Araujo AR; Neves FAR; de Carvalho JL; Rego EM; Saldanha-Araujo F
    Med Oncol; 2018 Nov; 36(1):3. PubMed ID: 30426231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives.
    Westaway SM; Preston AG; Barker MD; Brown F; Brown JA; Campbell M; Chung CW; Diallo H; Douault C; Drewes G; Eagle R; Gordon L; Haslam C; Hayhow TG; Humphreys PG; Joberty G; Katso R; Kruidenier L; Leveridge M; Liddle J; Mosley J; Muelbaier M; Randle R; Rioja I; Rueger A; Seal GA; Sheppard RJ; Singh O; Taylor J; Thomas P; Thomson D; Wilson DM; Lee K; Prinjha RK
    J Med Chem; 2016 Feb; 59(4):1357-69. PubMed ID: 26771107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays.
    Le Bihan YV; Lanigan RM; Atrash B; McLaughlin MG; Velupillai S; Malcolm AG; England KS; Ruda GF; Mok NY; Tumber A; Tomlin K; Saville H; Shehu E; McAndrew C; Carmichael L; Bennett JM; Jeganathan F; Eve P; Donovan A; Hayes A; Wood F; Raynaud FI; Fedorov O; Brennan PE; Burke R; van Montfort RLM; Rossanese OW; Blagg J; Bavetsias V
    Eur J Med Chem; 2019 Sep; 177():316-337. PubMed ID: 31158747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of histone demethylase KDM4 by ML324 induces apoptosis through the unfolded protein response and Bim upregulation in hepatocellular carcinoma cells.
    Kim SY; Hwang S; Lee BR; Hong JA; Sung YH; Kim I
    Chem Biol Interact; 2022 Feb; 353():109806. PubMed ID: 34999051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Based Screening of Tetrazolylhydrazide Inhibitors versus KDM4 Histone Demethylases.
    Małecki PH; Rüger N; Roatsch M; Krylova O; Link A; Jung M; Heinemann U; Weiss MS
    ChemMedChem; 2019 Nov; 14(21):1828-1839. PubMed ID: 31475772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
    Rotili D; Tomassi S; Conte M; Benedetti R; Tortorici M; Ciossani G; Valente S; Marrocco B; Labella D; Novellino E; Mattevi A; Altucci L; Tumber A; Yapp C; King ON; Hopkinson RJ; Kawamura A; Schofield CJ; Mai A
    J Med Chem; 2014 Jan; 57(1):42-55. PubMed ID: 24325601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Jmjd2/Kdm4 demethylases are required for expression of Il3ra and survival of acute myeloid leukemia cells.
    Agger K; Miyagi S; Pedersen MT; Kooistra SM; Johansen JV; Helin K
    Genes Dev; 2016 Jun; 30(11):1278-88. PubMed ID: 27257215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.